Wall Street calls: Piper upgrades Rivian, Mobileye; JPMorgan starts Rhythm Pharmaceuticals at overweight
2026-07-27 12:18:19
According to CNBC, Piper Sandler upgraded Rivian and Mobileye to overweight from neutral, saying both stocks are compelling. Piper cited Rivian's de-risked balance sheet, a smooth R2 ramp and an improved demand outlook, while saying Mobileye is nearing floor valuation and gaining control of its own destiny. The firm also initiated Williams-Sonoma at overweight with a $253 price target, and JPMorgan started Rhythm Pharmaceuticals at overweight with a Dec. 27 price target of $145. Other calls included Citizens' initiation of Sonida Senior Living at market outperform, Roth's initiation of Aduro Clean Technologies at buy, and UBS's upgrade of Cameco to buy from neutral after a recent pullback.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Strategy上周未买卖比特币
